Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Brett P. Monia Sells 1,160 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CEO Brett P. Monia sold 1,160 shares of Ionis Pharmaceuticals stock in a transaction on Friday, July 11th. The shares were sold at an average price of $41.74, for a total transaction of $48,418.40. Following the completion of the transaction, the chief executive officer owned 179,820 shares in the company, valued at approximately $7,505,686.80. This represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Ionis Pharmaceuticals Trading Down 1.0%

IONS stock traded down $0.41 on Friday, hitting $41.76. 1,266,278 shares of the company were exchanged, compared to its average volume of 1,622,328. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $52.34. The company has a debt-to-equity ratio of 2.63, a current ratio of 9.66 and a quick ratio of 9.62. The business's fifty day moving average is $37.11 and its two-hundred day moving average is $33.53. The stock has a market capitalization of $6.65 billion, a price-to-earnings ratio of -13.97 and a beta of 0.23.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.14. Ionis Pharmaceuticals had a negative net margin of 63.65% and a negative return on equity of 91.85%. The firm had revenue of $132.00 million during the quarter, compared to analyst estimates of $144.31 million. During the same quarter in the prior year, the business posted ($0.98) earnings per share. Ionis Pharmaceuticals's revenue for the quarter was up 10.9% compared to the same quarter last year. As a group, research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Xponance Inc. increased its position in shares of Ionis Pharmaceuticals by 1.7% in the fourth quarter. Xponance Inc. now owns 19,339 shares of the company's stock worth $676,000 after acquiring an additional 318 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Ionis Pharmaceuticals by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 21,826 shares of the company's stock worth $763,000 after acquiring an additional 373 shares in the last quarter. CWM LLC increased its position in shares of Ionis Pharmaceuticals by 18.7% in the first quarter. CWM LLC now owns 2,435 shares of the company's stock worth $73,000 after acquiring an additional 384 shares in the last quarter. Signaturefd LLC increased its position in shares of Ionis Pharmaceuticals by 45.6% in the first quarter. Signaturefd LLC now owns 1,382 shares of the company's stock worth $42,000 after acquiring an additional 433 shares in the last quarter. Finally, Treasurer of the State of North Carolina increased its position in shares of Ionis Pharmaceuticals by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 68,803 shares of the company's stock worth $2,405,000 after acquiring an additional 440 shares in the last quarter. Institutional investors and hedge funds own 93.86% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on IONS shares. Needham & Company LLC dropped their price target on shares of Ionis Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Redburn Atlantic assumed coverage on shares of Ionis Pharmaceuticals in a report on Monday, March 31st. They set a "neutral" rating and a $39.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a "neutral" rating in a report on Thursday, June 12th. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Ionis Pharmaceuticals in a report on Thursday, June 26th. Finally, Barclays raised shares of Ionis Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $51.00 to $57.00 in a report on Tuesday, July 1st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.13.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.